Janssen-Cilag International NV, a Johnson & Johnson company, announced today that it has submitted applications to the European Medicines Agency (EMA) to extend the marketing authorization application (MAA) for Tremfya (guselkumab) to include the treatment of adult patients with ulcerative colitis and patients with Crohn's disease.

The submission is based on the results of two Phase III trials/

'People with chronic immune-mediated diseases such as ulcerative colitis and Crohn's disease often spend a considerable amount of time switching between treatments in search of relief and lasting remission,' said David Lee, Head of Global Immunology Therapeutic at Janssen.

This submission is an important milestone in our mission to develop novel and effective therapies for the millions of people worldwide living with ulcerative colitis and Crohn's disease who experience persistent and debilitating symptoms.

Copyright (c) 2024 CercleFinance.com. All rights reserved.